{"news_desk": "Business", "print_page": "3", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By KATIE THOMAS", "person": [{"rank": 1, "role": "reported", "firstname": "Katie", "organization": "", "lastname": "THOMAS"}]}, "abstract": "Valeant Pharmaceuticals says it is being investigated by Securities and Exchange Commission; has come under scrutiny for its high drug prices and dealings with mail-order pharmacy.", "type_of_material": "News", "word_count": "641", "lead_paragraph": "The beleaguered drug maker, already under scrutiny for its steep price increases, earlier canceled its fourth-quarter earnings report.", "pub_date": "2016-03-01T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Valeant Pharmaceuticals Is Under S.E.C. Investigation", "print_headline": "<span data-tag=\"tight__4\">After Tumultuous Day for Valeant, Latest Blow Is an S.E.C. Investigation</span>"}, "snippet": "The beleaguered drug maker, already under scrutiny for its steep price increases, earlier canceled its fourth-quarter earnings report.", "multimedia": [{"height": 126, "url": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 400, "url": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/03/01/business/01VALEANTSUPERREFER/01VALEANTSUPERREFER-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2016/03/01/business/valeant-pharmaceuticals-is-under-sec-investigation.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Securities and Exchange Commission", "name": "organizations"}, {"rank": "4", "is_major": "N", "value": "Pearson, John Michael (1959- )", "name": "persons"}], "blog": [], "_id": "56d4c6f438f0d811294b816c", "source": "The New York Times"}